1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Strategy

Abbott’s Metabolic Health Biowearable Gets ‘Extremely Positive’ UK Reception; Next Up, US Filing

“We’re so steeped in scientific and medical expertise that we never really learned how to talk to or with regular people,” says Abbott CEO Robert Ford.

 
• By Marion Webb

Lingo, based on Abbott’s FreeStyle Libre diabetes management technology but targeted to the consumer market, works with a companion app to identify user habits that negatively impact their health and guide them in modifying behaviors accordingly. Olivier Ropars, division VP of Lingo Biowearables, discusses the company's recent UK launch and future plans.

• Source: Medtech Insight

It’s been two months since Abbott’s new biosensing wearable Lingo, designed to enable consumers to monitor their metabolic health, made its debut in the United Kingdom. And thus far, the reception in that test market has been “extremely positive,” Olivier Ropars, division vice president of Abbott’s Lingo Biowearables told Medtech Insight at the HLTH conference last week.

Abbott plans to file for US Food and Drug Administration clearance of the device by year-end and then make Lingo...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Haleon Takes Full Control Of China JV

 
• By Tom Gallen

Haleon finalizes deal to make its China joint venture a wholly-owned subsidiary in move to "drive category growth in one of the fastest growing OTC markets globally."

Opella Claims Sustainability Leadership Position With Global B Corp Certification

 
• By Tom Gallen

Cutting greenhouse gas emissions and obtaining its electricity from renewable sources has helped Opella earn global B Corp certification.

People On The Move: Appointments At Haleon, Nestlé, Cornerstone

 
• By Tom Gallen

A round up of the latest European health & wellness moves: Haleon names Lauder's Haney as R&D chief; Nestle nominates Isla for board chair; Cornerstone appoints Stada's Ed Round.

Navamedic Adds OTC Naloxone With DNE Pharma Acquisition

 
• By Tom Gallen

Norway's Navamedic will move into the addiction treatment market with the acquisition of DNE Pharma, adding to its portfolio an OTC opioid overdose reversal spray.

More from Business

Stada CEO Has ‘Big Hopes’ For AI-Driven Personalized Healthcare

 
• By David Ridley

“Harnessing AI’s astounding abilities to improve people’s lives and relieve overburdened healthcare systems is one of the great opportunities of our time,” argues Stada CEO Peter Goldschmidt in the company's Health Report 2025.

People On The Move: Appointments At Haleon, Nestlé, Cornerstone

 
• By Tom Gallen

A round up of the latest European health & wellness moves: Haleon names Lauder's Haney as R&D chief; Nestle nominates Isla for board chair; Cornerstone appoints Stada's Ed Round.

Navamedic Adds OTC Naloxone With DNE Pharma Acquisition

 
• By Tom Gallen

Norway's Navamedic will move into the addiction treatment market with the acquisition of DNE Pharma, adding to its portfolio an OTC opioid overdose reversal spray.